RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in japanese patients with advanced cancer

Auteur(s) / Author(s)

ARAKI Kiyonori (1) ; NOGUCHI Yasushi (2) ; HIROUCHI Takashi (2) ; YOSHIKAWA Emiko (2) ; KATAOKA Sayo (2) ; SILVERNI Lucila (2) ; MIYAZAWA Hitoshi (2) ; KUZUHARA Hiroshi (2) ; SUZUKI Chiaki (2) ; SHIMADA Yukari (2) ; HAMASATO Shinji (2) ; MAEDA Nagamasa (2) ; SHIMAMURA Yoshiyuki (3) ; OGAWA Yasuhiro (4) ; OHTSUKI Yuji (5) ; FUJIMOTO Shigeyoshi (2) ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) Department of Medicine, Atago General Hospital, Kochi 780-0056, JAPON
(2) Department of Immunology, Kochi Medical School, Nankoku, Kochi 783-8505, JAPON
(3) Department of Surgery, Chibanishi General Hospital, Matsudo, Chiba 270-2251, JAPON
(4) Department of Radiology, Kochi Medical School, Nankoku, Kochi 783-8505, JAPON
(5) Department of Pathology, Kochi Medical School, Nankoku, Kochi 783-8505, JAPON

Résumé / Abstract

Autologous cancer-specific bulk CTLs are unlikely to be induced by in vitro CTL generation (ivtCTLG) using peripheral blood mononuclear cells (PBMCs) of cancer patients when autologous cancer cells are used as in vitro stimulators. However, autologous cancer-specific bulk CTLs are frequently activated when allogeneic cancer cells are used as in vitro stimulators, regardless of the type of cancer cell. We have developed a cancer-specific immunotherapy called modified CTL therapy, which involves adoptive immunotherapy of autologous cancer-specific bulk CTLs after active immunization of autologous or allogeneic cancer cells screened as in vitro stimulators according to their ability to induce autologous cancer-specific CTLs (ACS.CTLs). Cancer did not regress in patients in whom ACS,CTLs were not induced by ivtCTLG using the patients' PBMCs in therapy. Cancer regression, albeit temporary, occurred solely in patients under the immunological condition that ACS.CTLs were induced by ivtCTLG using PBMCs through the therapy. The induction of ACS,CTLs by ivtCTLG using patient PBMCs in therapy was related to patients' HLA class II antigens. HLA DR8 was seen more frequently in ACS.CTL-inducible patients than in ACS.CTL-uninducible patients (P=0.051). On the contrary, HLA DQ3 was seen more frequently in ACS.CTL-uninducible patients (P=0.055). On the other hand, the success in therapy, albeit temporary, was related mainly to patients' HLA class I antigens. HLA B61 was seen more frequently in patients whose therapy proved effective than in patients whose therapy proved ineffective (P=0.018), HLA Cw7 was seen more frequently in therapy-ineffective patients (P=0.040).

Revue / Journal Title

International journal of oncology    ISSN  1019-6439 

Source / Source

2000, vol. 17, no6, pp. 1107-1118 (35 ref.)

Langue / Language

Anglais

Editeur / Publisher

Editorial Academy of the International Journal of Oncology, Athens, GRECE  (1992) (Revue)

Mots-clés anglais / English Keywords

Malignant tumor

;

Advanced stage

;

T-Lymphocyte

;

Cytotoxicity

;

Adoptive immunization

;

Immunotherapy

;

Class I histocompatibility antigen

;

Class II histocompatibility antigen

;

HLA-System

;

Major histocompatibility system

;

Treatment

;

Regression

;

Active immunization

;

Japan

;

Human

;

Asia

;

Mots-clés français / French Keywords

Tumeur maligne

;

Stade avancé

;

Lymphocyte T

;

Cytotoxicité

;

Immunisation adoptive

;

Immunothérapie

;

Antigène histocompatibilité classe I

;

Antigène histocompatibilité classe II

;

Système HLA

;

Système histocompatibilité majeur

;

Traitement

;

Régression

;

Immunisation active

;

Japon

;

Homme

;

Asie

;

Mots-clés espagnols / Spanish Keywords

Tumor maligno

;

Estadio avanzado

;

Linfocito T

;

Citotoxicidad

;

Inmunización adoptiva

;

Inmunoterapia

;

Antígeno histocompatibilidad clase I

;

Antígeno histocompatibilidad clase II

;

Sistema HLA

;

Sistema histocompatibilidad mayor

;

Tratamiento

;

Regresión

;

Inmunización activa

;

Japón

;

Hombre

;

Asia

;

Localisation / Location

INIST-CNRS, Cote INIST : 26333, 35400009149536.0050

Nº notice refdoc (ud4) : 790379



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas